These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Susceptibility of clinical isolates to expanded-spectrum beta-lactams alone and in the presence of beta-lactamase inhibitors. Qadri SM; Ueno Y; Cunha BA Chemotherapy; 1996; 42(5):334-42. PubMed ID: 8874972 [TBL] [Abstract][Full Text] [Related]
7. Extended-spectrum beta-lactamases: the role of inhibitors in therapy. Amyes SG; Miles RS J Antimicrob Chemother; 1998 Oct; 42(4):415-7. PubMed ID: 9818738 [No Abstract] [Full Text] [Related]
13. Prospects for expanding the use of beta-lactamase inhibitors. Thomson CJ; Amyes SG J Med Microbiol; 1992 Nov; 37(5):297-8. PubMed ID: 1433250 [No Abstract] [Full Text] [Related]
14. A novel method for determination of beta-lactamase using the agar dilution method. Tsuji H Chemotherapy; 1983; 29(6):401-7. PubMed ID: 6360576 [TBL] [Abstract][Full Text] [Related]
15. Combination beta-lactam and beta-lactamase-inhibitor therapy: pharmacokinetic and pharmacodynamic considerations. Dudley MN Am J Health Syst Pharm; 1995 Mar; 52(6 Suppl 2):S23-8. PubMed ID: 7606586 [TBL] [Abstract][Full Text] [Related]
16. In-vitro evaluation of the four beta-lactamase inhibitors: BRL42715, clavulanic acid, sulbactam, and tazobactam. Muratani T; Yokota E; Nakane T; Inoue E; Mitsuhashi S J Antimicrob Chemother; 1993 Sep; 32(3):421-9. PubMed ID: 8262864 [TBL] [Abstract][Full Text] [Related]
17. Empirical use of β-lactam-β-lactamase inhibitors. Chan K; Mack D; El-Mugamar H Infect Dis (Lond); 2016 Sep; 48(9):703-4. PubMed ID: 27207186 [No Abstract] [Full Text] [Related]